ReviewFrontiers in immunology2019
Recurrent and
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 66 citations in OpenAlex.
- Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients.Frontiers in immunology · 2022Trial
- Article
- Finerenone in kidney transplantation: an underinvestigated agent: review of available evidence, existing gaps, and future directions.Clinical transplantation and research · 2026Review
- Full-House Nephropathy Without Lupus Manifesting During Acute Kidney Allograft Rejection: A Case Report.Clinical case reports · 2026Article
- Critical role of complement in antibody mediated rejection in kidney transplantation.World journal of transplantation · 2025Review
- Recurrence of Glomerular Diseases (GN) After Kidney Transplantation: A Narrative Review.Journal of clinical medicine · 2025Review
- Post-transplant IgA nephropathy: a rapidly evolving field of kidney transplant medicine.Journal of nephrology · 2025Review
- Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.Clinical kidney journal · 2024Review
- Access to Waitlisting and Posttransplant Outcomes in Patients With Failed Kidney Allografts Secondary to Recurrent Glomerulonephritis.Transplantation direct · 2024Article
- Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options.International journal of molecular sciences · 2024Review
- Recurrence of Idiopathic Membranous Nephropathy in the Kidney Allograft: A Systematic Review.Biomedicines · 2024Review
- Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives.Journal of nanobiotechnology · 2024Review
- Clinical Impacts of Allograft Biopsy in Renal Transplant Recipients 10 Years or Longer After Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Post-Transplant Glomerulonephritis: Challenges and Solutions.International journal of nephrology and renovascular disease · 2024Review
- Recurrent Membranoproliferative Glomerulonephritis After Kidney Transplantation: Risk Factors and Impact on Graft Survival.Annals of transplantation · 2023Article
- Label-free MXene-assisted field effect transistor for the determination of IL-6 in patients with kidney transplantation infection.Mikrochimica acta · 2023Article
- Glomerulonephritis: immunopathogenesis and immunotherapy.Nature reviews. Immunology · 2023Review
- A 78-Year-Old Man with Chronic Kidney Disease and Monoclonal Gammopathy Who Developed Post-Transplant C3 Glomerulopathy - Recurrence or De Novo? A Case Report and Literature Review.The American journal of case reports · 2023Review
- Case report: Early onsetFrontiers in pediatrics · 2023Article
- Defining diagnostic trajectories in patients with podocytopathies.Clinical kidney journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence, pathogenesis, predictors, and natural course of patients with recurrent glomerulonephritis (GN) occurring after kidney transplantation remains incompletely understood, including whether there are differences in the outcomes and advances in the treatment options of specific GN subtypes, including those with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.